Results: A high dose of DM significantly produced serotonin syndrome in mice. In addition, treatment with DM resulted in a significant increase in 5-HT1A receptor mRNA expression but not that of 5-HT2A receptor in the hypothalamus of mice. Furthermore, WAY100635, but not MDL11939, significantly attenuated increases in hypothalamic serotonin level, serotonergic behaviors and hypothermia induced by DM. Conclusion: Up-regulation of 5-HT1A receptor is essential for serotonin syndrome induced by DM in mice [This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea].
Methods: Mice were pretreated with rottlerin, a pharmacological inhibitor of PKC-δ, 30 min before DM administration. Scores of serotonin syndrome (i.e. reciprocal forepaw treading, lateral head-weaving, hind-limb abduction, tremor, Straub tail and flat body posture) were assessed during 30 min after DM. In addition, rectal temperature was measured 30 min after DM. Serotonin levels and 5-HT1A receptor mRNA expression were examined in the hypothalamus 2 h after DM. Results: A high dose of DM resulted in a specific induction of PKC-δ out of PKC-α, PKC-β1, PKC-β2, PKC-ξ, PKC-δ in the hypothalamus of mice. Rottlerin significantly attenuated serotonergic behaviors induced by DM. In addition, rottlerin protected increases in 5-HT1A receptor mRNA expression and serotonin level induced by DM in wild-type mice. Consistently, genetic inhibition of PKC-δ protected serotonergic behaviors and increases in serotonin level, mRNA expression of 5-HT1A receptor induced by DM. Conclusion: Endogenous PKC-δ gene mediates serotonin syndrome induced by DM in mice [This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea].
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PKCδ gene facilitates cognitive impairment induced by low doses of methamphetamine (MA) in mice Abstract Objective: We suggested that the cognitive impairment induced by repeated MA treatment in mice is a useful model of the cognitive deficits in schizophrenia and MA psychosis. We also demonstrated that minocycline, an antibiotic possessing antiinflammatory activity, improves cognitive impairment induced by MA. It is well-known that protein kinase C (PKC) mediates neuroinflammation. Therefore, we investigated a specific role of PKC in response to cognitive impairment induced by MA. Method: To achieve a better understanding whether PKC expression can be altered by repeated treatment with MA. We examined changes in the expression of PKCα, PKCβ 1 , PKCβ 2 , PKCζ, and PKCδ in the prefrontal cortex (PFC) after the final MA treatment. Because PKCδ expression is selectively increased after the last MA, we applied PKCδ knock-out (KO) mice in this study. We evaluated relationship between novel object recognition test (NORT), phosphorylation of extracellular signal-regulated kinase ½ (p-ERK½), and phosphorylation of PKCδ (p-PKCδ) in the PFC. Result: Repeated treatment with MA resulted in cognitive impairment as evaluated by NORT. This effect lasted, at least, for 28 days after the final MA treatment. Correlation study indicated that cognitive impairment parallels p-PKCδ expression. P-ERK½ expression increased in the mice exposed to the novel objects in the absence of MA, but it was decreased in the presence of MA. Genetic inhibition of PKCδ attenuated MA-induced decrease in p-ERK½ expression. Posttreatment with antipsychotic clozapine significantly protected cognitive impairment and alteration in p-ERK½ and p-PKCδ. 
Conclusion
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Association between catecholamine metabolites after antidopaminergic intervention and mental condition in healthy subjects Abstract Objective: Investigations of the association between the peripheral measurable catecholamine metabolites and the response to antipsychotics and psychopathology in schizophrenia patients have shown incongruent results. Very little is factually known about their possible association with the general mental condition apart from specific psychiatric disorders. Methods: Catecholamine metabolites in plasma and 24h urine were determined in seventy-two healthy volunteers before and after 1-week administration of reserpine, aripiprazole, haloperidol or placebo in a randomized, single-blinded study. At the same time-points their mental condition was assessed using objective and subjective measures. Results: A significant increase of the concentration of the main metabolites of dopamine (homovanillic acid (HVA) in urine) and norepinephrine (3-methoxy-4-hydroxyphenylglycol in plasma as well as vanillyl mandelic acid concentration in 24h urine) occurred solely in the group receiving reserpine.
The HVA plasma concentration measured after the psychopharmacological intervention correlated significantly with some clinical scores (PANSS total, PANSS negative, PANSS cognitive) in the total group of participants who received the antidopaminergic medication. There also was a negative correlation between the HVA levels and the subjective assessments of achievement potential, the ability to concentrate and the general well-being. On the opposite, for the self-assessment of exhaustion and apathy we found statistically significant positive correlations. Discussion: Altogether in our study solely reserpine caused a verifiable increase of some catecholamine metabolites probably as a result from the blockade of the vesicular monoamine transporter and the increased catabolism of monoamines by monoamine oxidase. Further the peripheral levels of monoamine metabolites were related to certain mental functions. Observed in healthy subjects, not affected by any psychiatric disorder, our results decouple this association from any specific pathological state, indicating a fundamental relationship.
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Haloperidol aggravates heart failure induced by pressure overload in mice through inhibition of sigma1-receptor Yasaharu Shinoda, Kohji Fukunaga, Hideaki Tagashira Tohoku University, Japan Abstract Haloperidol was commonly used for schizophrenia patients as D2 receptor antagonist. It has been known that haloperidol-induced cardiac sudden death is serious adverse event for schizophrenia patients. Haloperidol antagonizes not only D2 receptor but also σ 1 -receptor (σ 1 R), and we previously reported that σ 1 R stimulation ameliorates cardiac dysfunction by restoring mitochondrial Ca 2+ mobilization in transverse aortic constriction (TAC) mice. In the cardiomyocytes, σ 1 R is associated with IP 3 receptor in the sarcoplasmic reticulum (SR) and promotes mitochondrial Ca 2+ mobilization from SR. Here we found that haloperidol impairs mitochondrial Ca 2+ mobilization and promotes cardiac hypertrophy via σ 1 R inactivation in primary cultured cardiomyocytes. The σ 1 R inactivation by haloperidol also aggravated Ang II-induced impaired mitochondrial Ca 2+ mobilization and ATP production. Inversely, σ 1 R agonist SA4503 ameliorated Ang II-induced impaired mitochondrial Ca 2+ mobilization and ATP production. Our observations suggest that haloperidol promotes progression of heart failure via impairment of σ 1 R-induced mitochondrial ATP production.
